Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

McKenzie, Steven E.

< Back

Profile

sem101

Steven E. McKenzie, MD, PhD

Contact Dr. McKenzie

1020 Locust Street
Suite 394
Philadelphia, PA 19107

215-955-3900
215-923-3836 fax

Research & Clinical Interests

Dr. McKenzie directs two major research projects. The first project involves vascular biology, with a focus on immune-mediated thrombocytopenia and thrombosis syndromes. This work, done in collaboration with Dr. Michael Reilly, led to the first model of heparin-induced thrombocytopenia and thrombosis. New work on effects of elevated cholesterol and athrosclerosis on HITT, and on microparticles and tissue factor, is ongoing.

Publications

Most Recent Peer-Reviewed Publications

  1. The SSC platelet immunology register of VITT and VIITP: Toward standardization of laboratory and clinical parameters
  2. Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy
  3. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology
  4. PCTP contributes to human platelet activation by enhancing dense granule secretion
  5. Platelet FcγRIIA in immunity and thrombosis: Adaptive immunothrombosis
  6. Platelets release mitochondrial antigens in systemic lupus erythematosus
  7. Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing
  8. FcgRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus
  9. Apoptosis signal-regulating kinase 1 regulates immune-mediated thrombocytopenia, thrombosis, and systemic shock
  10. Clinical Transformation in Care for Patients With Sickle Cell Disease at an Urban Academic Medical Center
  11. GRK6 regulates the hemostatic response to injury through its rate-limiting effects on GPCR signaling in platelets
  12. Platelets disseminate extracellular vesicles in lymph in rheumatoid arthritis
  13. Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia
  14. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y12 inhibition
  15. Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration
  16. 5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies
  17. Erratum: TULA-2 protein phosphatase suppresses activation of Syk through the GPVI platelet receptor for collagen by dephosphorylating Tyr(P)346, a regulatory site of Syk (The Journal of Biological Chemistry (2016) 291 (22427-22441) DOI: 10.1074/jbc.M116.743732)
  18. Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia
  19. TULA-2 (T-Cell Ubiquitin Ligand-2) Inhibits the Platelet Fc Receptor for IgG IIA (FcγRIIA) Signaling Pathway and Heparin-Induced Thrombocytopenia in Mice
  20. TULA-2 protein phosphatase suppresses activation of syk through the GPVI platelet receptor for collagen by dephosphorylating Tyr(P)346 a regulatory site of syk
  21. Mice expressing low levels of CalDAG-GEFI exhibit markedly impaired platelet activation with minor impact on hemostasis
  22. Identification of novel Syk-independent functional roles of FcγRIIa in platelet outside-in signaling using transgenic mice expressing human FcγRIIa
  23. Syk inhibition in ischemic stroke
  24. Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia
  25. The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21)